spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

GE sets new standard for monoclonal antibody purification: Up to 40% increase in capacity

GE Healthcare Life Sciences

GE Healthcare introduces a new Protein A chromatography resin, MabSelect PrismA

CHALFONT ST. GILES, UK and UPPSALA, SWEDEN – 25 September 2017 – GE Healthcare introduces a new Protein A chromatography resin, MabSelect PrismA, which will help biopharmaceutical manufacturers improve their monoclonal antibody (mAb) purification capacity by up to 40 percent [1]. The resin is also significantly more alkaline-stable[2], meaning that MabSelect PrismA can be cleaned with a higher concentration of sodium hydroxide to better control cross-contamination and bioburden risks[3]

Monoclonal antibody products (mAbs) are the largest and fastest growing segment of biologics; the market revenue is estimated to reach USD 125 billion in 2020[4]. Nearly all mAbs on the market use Protein A resin as the first purification step because it offers an efficient, common platform for different mAbs[5]. Protein purification is an obligatory step in biomanufacturing, and the target protein that is extracted from the cell culture is used to make the final biopharmaceutical product.

The efficiency with which cells produce antibodies during the biomanufacturing process has improved radically during the past years, creating pressure on the purification technologies. The result has been increased processing times, and larger consumption of chromatography resins.

MabSelect PrismA addresses a number of key challenges, including the increased upstream titers[6]. The new resin is highly efficient due to its excellent binding capacity, which is critical, because it determines how much resin is needed to purify a certain amount of protein.

“Biopharma companies are constantly looking for more ways to increase their output, and Protein A has a critical role to support these efforts. The thorough research and development work that we have carried out to create MabSelect PrismA sets a new standard for mAb purification. To put it simply, with this chromatography resin our customers will be able to produce more biopharmaceuticals out of their existing manufacturing equipment. Protein purification is no longer a bottleneck, but driving higher productivity and shorter manufacturing lead times for our customers,” says Jan Makela, General Manager, BioProcess, GE Healthcare Life Sciences.

GE Healthcare’s customers can order MAbSelect PrismA samples as of today. The product will be fully available for orders during the first half of 2018.

[1] Compared to GE Healthcare Life Sciences’ MabSelect SuRe LX.
[2] Compared to GE Healthcare Life Sciences’ MabSelect SuRe LX.
[3] Bioburden is the degree of microbial contamination or microbial load, the number of organisms contaminating an object (Medical Dictionary for the Health Professions and Nursing)
[4] Ecker DM1, Jones SD, Levine HL (2015): The therapeutic monoclonal antibody market
[5] Downstream processing of monoclonal antibodies—Application of Platform Approaches (2017)
[6] Titer characterizes upstream manufacturing efficiency that indicates that more desired product is manufactured using the same or less amount of fluid or filled bioreactor volume. (BioProcess International: 30 Years of Upstream Productivity Improvements)

About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For more information about GE Healthcare, visit our website at www.gehealthcare.com.

phone + 1 800 526 3593
email cs-us@ge.com
web www.gelifesciences.com
email P.O. Box 643065 Pittsburgh, PA 15264-3065 United States of America
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Avacta and Leeds University awarded £3.8m Medical Research Council funding to develop new diagnostic tests


More info >>


White Papers

Clinical Trials in Russia Orange Paper: 2nd Quarter 2014

Synergy Research Group

The Ministry of Health of Russian Federation approved 194 new clinical trials of all types including local and bioequivalence studies during the 2nd Quarter of 2014 (3% less than at the same period of the last year). The main contribution to the total number of studies was made by multinational multi-center clinical trials (MMCT) and the number of these studies stayed the same as in Q2 2013 – 81 studies. The number of bioequivalence studies (BE) decreased from 76 studies in Q2 2013 to 59 in Q2 2014, a 22% decrease from last year’s figure. The number of local clinical trials (LCT) increased from 42 in Q2 2013 to 54 clinical trials in Q2 2014.
More info >>

Industry Events

CPhI India 2017

27-30 November 2017, Bombay Exhibition Centre & MMRDA Grounds, BKC

Connect, network and interact with 1,400+ exhibitors at India's largest and leading pharmaceutical event. CPhI and P-MEC India is the gateway for you to meet the movers and shakers in India’s pharma industry to source high quality pharma solutions at the most competitive prices. Register today for free via: gotocphi.com/india2017
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement